Hallmeyer Sigrun, Thompson Michael A, Fitzpatrick Veronica, Liao Yunqi, Mullane Michael P, Medlin Stephen C, Copeland Kenneth, Weese James L
Advocate Aurora Health, 3075 Highland Parkway, Downers Grove, IL 60515, USA.
Aurora Cancer Care, Advocate Aurora Health, 750 W Virginia Street, Milwaukee, WI 53204, USA.
Biol Methods Protoc. 2023 Feb 14;8(1):bpad002. doi: 10.1093/biomethods/bpad002. eCollection 2023.
The objective of this study is to explore the characteristics of the subset of patients with hematologic malignancies (HMs) who had little to no change in SARS-CoV-2 spike antibody index value levels after a third mRNA vaccine dose (3V) and to compare the cohort of patients who did and did not seroconvert post-3V to get a better understanding of the demographics and potential drivers of serostatus.
This retrospective cohort study analyzed SARS-CoV-2 spike IgG antibody index values pre and post the 3V data on 625 patients diagnosed with HM across a large Midwestern United States healthcare system between 31 October 2019 and 31 January 2022.
To assess the association between individual characteristics and seroconversion status, patients were placed into two groups based on IgG antibody status pre and post the 3V dose, (-/+) and (-/-). Odds ratios were used as measures of association for all categorical variables. Logistic regressions were used to measure the association between HM condition and seroconversion.
HM diagnosis was significantly associated with seroconversion status ( = 0.0003) with patients non-Hodgkin lymphoma six times the odds of not seroconverting compared with multiple myeloma patients ( = 0.0010). Among the participants who were seronegative prior to 3V, 149 (55.6%) seroconverted after the 3V dose and 119 (44.4%) did not.
This study focuses on an important subset of patients with HM who are not seroconverting after the COVID mRNA 3V. This gain in scientific knowledge is needed for clinicians to target and counsel these vulnerable patients.
本研究的目的是探讨血液系统恶性肿瘤（HM）患者亚组的特征，这些患者在接种第三剂mRNA疫苗（3V）后严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突抗体指数值水平变化很小或没有变化，并比较3V后发生血清转化和未发生血清转化的患者队列，以更好地了解血清状态的人口统计学特征和潜在驱动因素。
这项回顾性队列研究分析了2019年10月31日至2022年1月31日期间，在美国中西部一个大型医疗系统中诊断为HM的625例患者在3V前后的SARS-CoV-2刺突IgG抗体指数值数据。
为了评估个体特征与血清转化状态之间的关联，根据3V剂量前后的IgG抗体状态，将患者分为两组，（-/+）和（-/-）。比值比用作所有分类变量的关联度量。逻辑回归用于衡量HM病情与血清转化之间的关联。
HM诊断与血清转化状态显著相关（P = 0.0003），非霍奇金淋巴瘤患者血清未转化的几率是多发性骨髓瘤患者的6倍（P = 0.0010）。在3V前血清阴性的参与者中，149例（55.6%）在3V剂量后发生血清转化，119例（44.4%）未发生血清转化。
本研究关注的是COVID mRNA 3V后未发生血清转化的HM患者的一个重要亚组。临床医生需要这些科学知识来针对和咨询这些脆弱的患者。
